Publications

Logos of journals including: Nature Cancer, Nature Chemical Biology, Science Translational Medicine, Angewante Chemie, Cell Chemical Biology.

 

  1. Targeting LRRK2 mutations in Parkinson's disease. Robert K. Leśniak, R. Jeremy Nichols, Mark Smith and Thomas J. Montine. Future Medicinal Chemistry, 2022, 14, NO. 16

  2. Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors. Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, Grace Lam, Khanh C. Nguyen, J. William Langston, Mark Smith and Thomas J. Montine. Eur. J. Med. Chem., 2022, 242, 114693

  3. Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors. Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, Grace Lam, Khanh C. Nguyen, J. William Langston, Mark Smith, and Thomas J. Montine. ACS Medicinal Chemistry Letters, 2022, 13 (6), 981-988

  4. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy. R. K. Lesniak, R. J. Nichols, M. Schonemann, J, Zhao, C. R. Gajera, W. L. Fitch, G. Lam, K. C. Nguyen, M. Smith and T. J. Montine. Eur. J. Med. Chem., 2022, 229, 114080

  5. Peptidomimetics therapeutics for retinal disease. D. E. Parsons, S. H. Lee, Y J. Sun, G. Velez, A. G. Bassuk, M. Smith and V. B. Mahajan. Biomolecules, 2021, 11, 339.

  6. Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS/GGPPS. S. Kabeche, J. Aida, T. Akther, T. Ichikawa, A. Ochida, M. J. Pulkoski-Gross, M. Smith, P. S. Humphries and E. Yeh. Bioorg. Med. Chem. Lett., 2021, 41, 127978.

  7. Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP. J. A. Carozza, J. A. Brown, V. Bohnert, D. Fernandez, Y. AlSaif, R. E. Mardjuki, M. Smith and L. Li. Cell Chem. Bio., 2020, 27, 1–12.

  8. Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. J. A. Carozza, V. Böhnert, K. C. Nguyen, G. Skariah, K. E. Shaw, J. A. Brown, M. Rafat, R. v Eyben, E. E. Graves, J, S, Glenn, M. Smith and L. Li. Nature Cancer, 2020, 1, 184.

  9. PI4KIII is a therapeutic target in chromosome 1q amplified lung adenocarcinoma. X. Tan, P. Banerjee, E. A. Pham, F. U. N. Rutaganira, K. Basu, N. Bota-Rabassedas, H-Fu Guo, C. L. Grzeskowiak, X. Liu, J. Yu, L. Shi, D. H. Peng, B. L. Rodriguez, J. Zhang, V. Zheng, D. Y. Duose, L. M. Solis, B. Mino, M. G. Raso, C. Behrens, I. I. Wistuba, K. L. Scott, M. Smith, K. Nguyen, G. Lam, I. Choong, A. Mazumdar, J. L. Hill, D. L. Gibbons, P. H. Brown, W. K. Russell, K. Shokat, C. J. Creighton, J. S. Glenn and Jonathan M. Kurie. Science Translational Medicine, 2020, 12, eaax3772.

  10. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization. P. A. Allegretti, T. M. Horton, Y. Abdolazimi, H. P. Moeller, B. Yeh, M. Caffet, M. Guillerminal, M. Smith and J. P. Annes. Bioorg. Med. Chem. Lett., 2020, 28, 115193

  11. SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway. H-D. Chae, N. Cox, S. Capolicchio, J. W. Lee, N. Horikoshi, S. Kam, A. A. Ng, J. Edwards, T-L Butler, J. Chan, Y. Lee, G. Potter, M. C. Capece, C. W. Liu, S. Wakatsuki, M. Smith and K. Sakamoto. Bioorg. Med. Chem. Lett., 2019, 29, 2307.

  12. Zinc-chelating small molecules preferentially accumulate and function within pancreatic B-cells. T. M. Horton, P. A. Allegretti, S. Lee, H. P. Moeller, M. Smith and J. P. Annes. Cell Chem. Bio., 2018. 26, 213.

  13. A Gut Commensal-Produced Metabolite Mediates Colonization Resistance to Salmonella Infection. A. Jacobson, L. Lam, M. Rajendram, F. Tamburini, J. Honeycutt, T. Pharm, W. V. Treuren, K. Pruss, S. R. Stabler, K. Lugo, D. M. Bouley, J. G. Vilches-Moure, M. Smith, J. L. Sonnenburg, A. S. Bhatt, K. C. Huang and D. Monack. Cell Host & Microbe. 2018, 24, 4301.

  14. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signalling pathways. H-D. Chae, N. Cox, G. V. Dahl, N. J. Lacayo, K. L. Davis, S. Capolicchio, M. Smith and K. M. Sakamoto. Oncotarget, 2018, 9, 4301.

  15. CC-401 Promoted B-cell replication via pleiotropic consequences of DYRK1A/B inhibition. Y. Abdolazimi, S. Lee, H. Xu, P. A. Allegretti, T. M. Horton, B. Yeh, H. P. Moeller, D. McCutcheon, S. Aryaman, M. Smith, N. A. Armstrong and J. P. Annes. Endocrinology, 2018, 159, 3143.

  16. Integrin-Targeting Knotting Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation, N. Cox, J. Kintzing, M. Smith, G. Grant and J. R. Cochran. Angew. Chem. Int Ed., 2016, 55, 9894.

  17. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. R. M. Deans, D. W. Morgans, A. Okesli, S. Pillay, M. A. Horlbeck, M. Kampmann, L. A. Gilbert, A. Li, R. Mateo, M. Smith, J. S. Glenn, J. E. Carette, C. Khosla and M. C. Bassik. Nature Chem. Bio. 2016, 12, 361.